Treating multiple sclerosis with generic cladribine

被引：0
|
作者：
Alvarez-Gonzalez, C. [1 ,2 ]
Allen-Philbey, K. [2 ]
Mathews, J. [3 ]
Espasandin, M. [2 ]
Turner, B. P. [1 ,2 ]
Gnanapavan, S. [1 ,2 ]
Marta, M. [1 ,2 ]
Giovannoni, G. [1 ,2 ]
Baker, D. [1 ]
Schmierer, K. [1 ,2 ]
机构：
[1] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Neurosci, London, England
[2] Barts Hlth NHS Trust, Emergency Care & Acute Med Neurosci Clin Acad Grp, London, England
[3] Barts Hlth NHS Trust, Neurol & Med Safety, London, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1161
引用
收藏
页码：604 / 605
页数：2
相关论文
共 50 条
  • [21] Cladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension study
    Rieckmann, Peter
    Giovannoi, Gavin
    Cook, Stuart D.
    Greenberg, S.
    Chang, Peter
    Comi, Giancarlo
    Sorensen, Per Soelberg
    Vermersch, Patrick
    MULTIPLE SCLEROSIS, 2008, 14 : S161 - S162
  • [22] Oral cladribine in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRIbine tablets Treating multiple sclerosis orallY) extension study
    Giovannoni, G.
    Cook, S.
    Greenberg, S.
    Chang, P.
    Comi, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    JOURNAL OF NEUROLOGY, 2008, 255 : 206 - 206
  • [23] Expert opinion consensus on recommendations for treating relapsing multiple sclerosis with cladribine tablets in daily clinical practice
    Sorensen, P. Soelberg
    Centonze, D.
    Giovannoni, G.
    Montalban, X.
    Selchen, D.
    Vermersch, P.
    Wiendl, H.
    Yamout, B.
    Salloukh, H.
    Rieckmann, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 945 - 946
  • [24] Multiple sclerosis: Orally administered cladribine displays efficacy in multiple sclerosis trial
    Yates D.
    Nature Reviews Neurology, 2010, 6 (4) : 182 - 182
  • [25] Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
    Savic, Radojka M.
    Novakovic, Ana M.
    Ekblom, Marianne
    Munafo, Alain
    Karlsson, Mats O.
    CLINICAL PHARMACOKINETICS, 2017, 56 (10) : 1245 - 1253
  • [26] Development of oral cladribine for the treatment of multiple sclerosis
    Hartung, Hans-Peter
    Aktas, Orhan
    Kieseier, Bernd
    Comi, Giancarlo
    JOURNAL OF NEUROLOGY, 2010, 257 (02) : 163 - 170
  • [27] Cladribine to Treat Relapsing Forms of Multiple Sclerosis
    Giovannoni, Gavin
    NEUROTHERAPEUTICS, 2017, 14 (04) : 874 - 887
  • [28] Cladribine: An Investigational immunomodulatory agent for multiple sclerosis
    Brousil, Julie A.
    Roberts, Russel J.
    Schlein, Amanda L.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (10) : 1814 - 1821
  • [29] Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
    Radojka M. Savic
    Ana M. Novakovic
    Marianne Ekblom
    Alain Munafo
    Mats O. Karlsson
    Clinical Pharmacokinetics, 2017, 56 : 1245 - 1253
  • [30] Cladribine personalised dosing to treat multiple sclerosis
    Mao, Z.
    Alvarez-Gonzalez, C.
    Allen-Philbey, K.
    Turner, B.
    Gnanapavan, S.
    Marta, M.
    Mathews, J.
    Giovannoni, G.
    Baker, D.
    Schmierer, K.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 609 - 609
12345